[Potential combination of target therapy and radiation therapy in GI tract cancers]

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• ErbB receptor signaling pathways regulate cellular proliferation, migration, and differentiation.
• Aberrant ErbB signaling, including mutations and overexpression, drives cancer development.
• Tumor growth and metastasis involve complex interactions with the microenvironment, notably angiogenesis mediated by VEGF.

Purpose of the Study:

• To explore therapeutic strategies targeting ErbB receptors and VEGF pathways in solid tumors.
• To review the role of ErbB receptor alterations and VEGF in tumor progression.
• To discuss the clinical development of targeted therapies for gastrointestinal malignancies.

Main Methods:

• Review of literature on ErbB receptor signaling and VEGF-mediated angiogenesis.
• Analysis of therapeutic strategies including monoclonal antibodies and tyrosine kinase inhibitors (TKIs).
• Examination of clinical research in esophageal, rectal, pancreatic, and colic carcinomas.

Main Results:

• Activating mutations in ErbB receptors, such as extracellular deletions, promote uncontrolled tyrosine kinase activity.
• Targeted therapies like monoclonal antibodies and TKIs are under clinical investigation for ErbB-driven cancers.
• VEGF plays a critical role in tumor angiogenesis, and its inhibition can radiosensitize tumors or overcome radioresistance.

Conclusions:

• Targeting ErbB receptors and VEGF pathways represents a promising approach for solid tumor treatment.
• Monoclonal antibodies against VEGF are utilized in treating pancreatic and colic carcinomas.
• Further clinical research is essential to optimize the use of these targeted therapies in various gastrointestinal cancers.